Long Term Follow up of Recipients of Functional Islet Allografts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01999374|
Recruitment Status : Recruiting
First Posted : December 3, 2013
Last Update Posted : October 9, 2017
Since its inception, the Diabetes Research Institute (DRI) has made significant contributions to the field of diabetes, pioneering many of the techniques used in diabetes centers around the world. Through several clinical trials, DRI has demonstrated that diabetes can be successfully reversed as a result of islet cell transplant.
Over the years the following protocols in islet cell transplantation have been initiated: 2000/0329; 2000/0196; 2004/0205; 2000/024; 2006/0200; 2006/0508; 2006/0210.
All of the studies listed above will be source of study subjects for this study. Approximately 30 subjects are expected to be enrolled and followed in this trial.
After islet-cell transplantation in the parent studies, each subject receives maintenance immunosuppressive medications.
The purpose of this protocol is to collect additional follow-up for safety and efficacy from subjects with graft function after their completion in their parent study. It is expected that most subjects will retain measurable islet function and, in the islet-alone studies, continue to receive immunosuppressive medications at the time of completing their parent study.
|Condition or disease|
|Type 1 Diabetes Mellitus|
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Long Term Follow up of Recipients of Functional Islet Allografts|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||March 2020|
|Estimated Study Completion Date :||December 2021|
- Duration of sustained islet allograft function [ Time Frame: 3 years ]The primary endpoint is duration of sustained islet allograft function as determined by evidence from Mixed Meal Tolerance Test of c-peptide production. A c-peptide level >=0.3 ng/ml at 0, 60, or 90 minutes will be considered evidence of islet allograft function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01999374
|United States, Florida|
|Diabetes Research Institute||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Rodolfo Alejandro, MD 305-243-5321 firstname.lastname@example.org|
|Principal Investigator: Rodolfo Alejandro, MD|
|Principal Investigator:||Rodolfo Alejandro, MD||University of Miami|